Skip to content

Segmentation of Structural Abnormalities in Chronic Lung Diseases

Segmentation of Structural Abnormalities in Chronic Lung Diseases

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04760548
Acronym
NOVAA
Enrollment
800
Registered
2021-02-18
Start date
2008-01-01
Completion date
2024-02-17
Last updated
2024-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, COPD, Cystic Fibrosis, Interstitial Lung Disease

Brief summary

Lung structural abnormalities are complex, time-consuming, and may lack reproducibility to evaluate visually on CT scans. The study's aim is to perform automated recognition of structural abnormalities in CT scans of patients with chronic lung diseases by using dedicated software.

Detailed description

Three chronic lung diseases will constitute the target of the study, by using retrospective data from each lung disease: * Cystic fibrosis * Asthma and COPD * Interstitial lung diseases Dedicated algorithms will be developped for each disease condition.

Interventions

OTHERObservational study

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
CollaboratorOTHER_GOV
Collaborative NOVAA study group
CollaboratorUNKNOWN
Hôpital Haut Lévêque
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
3 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients with chronic lung disease and clinical examination, pulmonary function test, and CT acquired during a routine follow-up

Design outcomes

Primary

MeasureTime frameDescription
Validity of automated measurementFrom date of inclusion until the date of final quantification, assessed up to 12 monthsCorrelations and comparisons with other biomarker of the disease severity

Secondary

MeasureTime frameDescription
Correlation with pulmonary function testFrom date of inclusion until the date of final quantification, assessed up to 12 monthsCorrelation of quantitative measurement with pulmonary function
Longitudinal variation over timeFrom date of inclusion until the date of final quantification, assessed up to 12 monthsComparison of quantitative measurement at two time points
ReproducibilityFrom date of inclusion until the date of final quantification, assessed up to 12 monthsEvaluation of measurements when performed twice

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026